LoginAbraxane: Revised PBS listing from 1 July 2010
The PBS listing for Abraxane (nanoparticle albumin-bound paclitaxel) has changed effective from 1 July 2010.
PBS Indication Authority required: Metastatic breast cancer after failure of prior therapy. |
Abraxane, since its introduction and PBS reimbursement in May 2009, has provided an effective chemotherapy treatment for metastatic breast cancer – prolonging survival with overall fewer adverse reactions and greater patient convenience than solvent-based paclitaxel.1,2
Now, with the revised PBS listing, patients with metastatic breast cancer are no longer required to have received an anthracycline to access Abraxane via the PBS.
Before prescribing Abraxane, please refer to the Abraxane Product Information.
More information
 | Read the Abraxane Product Information. |
 | For more information, download the PBS More Information Request Form and fax to 1800 798 829. |
References
- Product Information: Abraxane. East Kew, VIC: Abraxis BioScience Australia Pty Ltd; 29 September 2008.
- Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-803. [Abstract | Full text]
Dates
Created by:
